intravenous immunoglobulin G (IVIG) + Placebo
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridium Difficile-associated Diarrhea (CDAD)
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Trial Timeline
Oct 1, 2003 → Apr 1, 2008
NCT ID
NCT00177970About intravenous immunoglobulin G (IVIG) + Placebo
intravenous immunoglobulin G (IVIG) + Placebo is a approved stage product being developed by Bayer for Clostridium Difficile-associated Diarrhea (CDAD). The current trial status is terminated. This product is registered under clinical trial identifier NCT00177970. Target conditions include Clostridium Difficile-associated Diarrhea (CDAD).
What happened to similar drugs?
8 of 20 similar drugs in Clostridium Difficile-associated Diarrhea (CDAD) were approved
Approved (8) Terminated (4) Active (12)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00177970 | Approved | Terminated |
Competing Products
20 competing products in Clostridium Difficile-associated Diarrhea (CDAD)